GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Capex-to-Operating-Cash-Flow

3SBio (HKSE:01530) Capex-to-Operating-Cash-Flow : 0.38 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is 3SBio Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

3SBio's Capital Expenditure for the six months ended in Dec. 2023 was HK$-369.99 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$982.62 Mil.

Hence, 3SBio's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.38.


3SBio Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for 3SBio's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Capex-to-Operating-Cash-Flow Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.73 0.73 0.46 0.34

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.32 0.59 0.31 0.38

Competitive Comparison of 3SBio's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, 3SBio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where 3SBio's Capex-to-Operating-Cash-Flow falls into.



3SBio Capex-to-Operating-Cash-Flow Calculation

3SBio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-770.388) / 2278.185
=0.34

3SBio's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-369.994) / 982.62
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio  (HKSE:01530) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


3SBio Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of 3SBio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (HKSE:01530) Business Description

Industry
Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Lou Jing 2305 Beneficiary of a trust
Jpmorgan Chase & Co. 2502 Approved lending agent
Hsbc Holdings Plc 2302 Custodian
Citic Securities Company Limited 2201 Interest of corporation controlled by you
Citron Pe Associates, L.p. 2201 Interest of corporation controlled by you
Citron Pe Funds Limited 2201 Interest of corporation controlled by you
Citron Pe Holdings Limited 2201 Interest of corporation controlled by you
Cpechina Fund, L.p. 2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited 2101 Beneficial owner
Tmf (cayman) Ltd. 2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited

3SBio (HKSE:01530) Headlines

No Headlines